Comparative study of the efficacy of combined nasal topical drug and topical decongestants in the treatment of acute rhinosinusitis

Close metadata

OBJECTIVE

To evaluate the efficacy of the drug Frinozol (nasal spray phenylephrinein 0.25% + cetirizine 0.25%) comparison with Rinostop Extra (nasal spray oxymetazoline 0.05%) in relation to nasal symptoms of rhinosinusitis, evaluated on rating scales, when using these drugs intranasally for 7 days in patients with acute viral and post-viral rhinosinusitis of mild (VAS 0-3) and moderate (VAS 3-7).

PATIENTS AND METHODS

The randomized open-label study included 60 ambulatory patients (men and women aged 18 to 60 years) with a verified diagnosis of acute rhinosinusitis (ARS) lasting no more than 120 hours. 1 group of patients took Frinozol (nasal spray phenylephrinein 0.25% + cetirizine 0.25%) for 2 sprays per each nostril 3 times a day for 7 days; 2 group — Rinostop Extra (nasal spray oxymetazoline 0.05%) at the same dose and the therapy regimen. We evaluated 3 visits (day 1, day 3, and day 7) with an ENT examination on each of them; questionnaires on the 1st and 3rd visits of nasal symptoms (nasal obstruction, rhinorrhea, hyposmia) on the visual analog scale (VAS) and Clinical Global Impression Scale-CGI. Active anterior rhinomanometry (AAR) was performed on the 1st, 2nd and 3rd visits using the PTS-14P-01 rhinomanometer Rinolan before and 20 minutes after the use of the drugs Frinozol and oxymetazoline 0.05%.

Keywords:

acute rhinosinusitis

phenylephrine

cetirizine

intranasal administration

topical decongestants

oxymetazoline

Authors:

Shakhova E.G.

Volgograd State Medical University

Received:

01.06.2020

Accepted:

06.07.2020

List of references:

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;29:1-464. https://doi.org/10.4193/Rhin20.600
Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe an underestimated disease. A GA(2)LEN study. Allergy. 2011;66:1216-1223. https://doi.org/10.1111/j.1398-9995.2011.02646.x
Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy. 2017;72:274-281. https://doi.org/10.1111/all.13042
Obaseki D, Potts J, Joos G, et al. The relation of airway obstruction to asthma, chronic rhinosinusitis and age: results from a population survey of adults. Allergy. 2014;69:1205-1214. https://doi.org/10.1111/all.12447
Sundaresan AS, Hirsch AG, Storm M, et al. Occupational and environmental risk factors for chronic rhinosinusitis: a systematic review. International Forum of Allergy & Rhinol. 2015;5:996-1003. https://doi.org/10.1002/alr.21573
Piatt Jr JH. Intracranial suppuration complicating sinusitis among children: an epidemiological and clinical study. J Neurosurg Pediatr. 2011;7:567-574. https://doi.org/10.3171/2011.3.PEDS10504
Jaume F, Quintó L, Alobid I, Mullol J. Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study). BMJ open. 2018; 8:e018788. https://doi.org/10.1136/bmjopen-2017-018788
Seresirikachorn K, Snidvongs K, Chitsuthipakorn W, et al. EPOS 2012 has better specificity compared to IDSA 2012 for diagnosing acute bacterial rhinosinusitis. Rhinology. 2018;56:241-244. https://doi.org/10.4193/Rhin17.261
Lim M, Lew-Gor S, Darby Y, Brookes N, Scadding G, Lund VJ. The relationship between subjective assessment instruments in chronic rhinosinusitis. Rhinology. 2007;45:144-147.
Remenschneider AK, D’Amico L, Gray ST, Holbrook EH, Gliklich RE, Metson R. The EQ-5D: A new tool for studying clinical outcomes in chronic rhinosinusitis. Laryngoscope. 2015;125:7-15. https://doi.org/10.1002/lary.24715
Van Oene CM, van Reij EJ, Sprangers MA, Fokkens WJ. Quality-assessment of diseasespecific quality of life questionnaires for rhinitis and rhinosinusitis: a systematic review. Allergy. 2007;62:1359-1371. https://doi.org/10.1111/j.1398-9995.2007.01482.x
Torp KD, Tschakovsky ME, Halliwill JR, Minson CT, Joyner MJ. β-Receptor agonist activity of phenylephrine in the human forearm. Journal of Applied Physiology. 2001;90(5):1855-1859. https://doi.org/10.1152/jappl.2001.90.5.1855.
Aronson JK. Meyler’s Side Effects of Drugs 16th Edition The International Encyclopedia of Adverse Drug Reactions and Interactions (7 Volumes Set). Elsevier Science; 2016:785-794.
Gurov AV, Yushkina MA. Differentiated approach to the therapy of nasal obstruction syndrome. Meditsinskiy sovet = Medical Council. 2017;(16):55-59. (In Russ.) https://doi.org/10.21518/2079-701X-2017-16-55-59
Karpishchenko SA, Ushakova SE, Fridman IL, Grinev IA, Pisarev VV, Merkulov ME. Resuit of an open, randomized, actively controlled study of efficacy and safety of new drug Freinozole nasal spray (Phenylephrine + Cetyrizine) in patients with acute respiratory infection Vestnik Otorinolaringologii. 2019;84(5):61-67. (In Russ.) https://doi.org/10.17116/otorino20198405161
Lewis TA, Bayless L, DiPesa AJ, Eckman JB, Gillard M, Libertine L, Young MA. 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. Bioorganic & medicinal chemistry letters. 2005;15(4):1083-1085. https://doi.org/10.1016/j.bmcl.2004.12.023
Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Annals Allergy, Asthma and Immunology. 2002;89(5):479-484.
Korsgren M, Andersson M, Borgå O, Larsson L, Aldén-Raboisson M, Malmqvist U, Greiff L. Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis. Annals of Allergy, Asthma & Immunology. 2007;98(4):316-321. https://doi.org/10.1016/S1081-1206(10)60876-9

Close metadata